Hospital leads way in cancer diagnosis after £14m boost
that UK Research and Innovation will invest £14 million into a consortium led by University Hospitals Coventry and Warwickshire NHS Trust - as part of the Industrial Strategy Challenge Fund.
The consortium ‘PathLAKE’ is a partnership with University of Warwick and Philips will collaborate on a three year project that will involve experts from NHS hospitals and universities at Belfast, Oxford and Nottingham.
The project will be hosted by the new UHCW Institute of Precision Diagnostics and Translational medicine to ensure rapid translation into clinical practice.
Together they could revolutionise the future of cancer care by speeding up the detection of some cancers while being more accurate, as well as paving the way for personalised care.
The funding will also be used to establish a ‘Data lake’ where anonymous patient data will be collected and used in research to look for patterns and trends - helping to further advance cancer care and other treatments.
Professor David Snead, consultant histopathologist and clinical lead, said: “Artificial intelligence used to be a thing of the future but I am delighted it is now set to transform how we do some pathology tests.
“It will mean that results will be quicker, more accurate and more sensitive than ever before, leading to improved patient care.
“This is an incredibly exciting time for the future of cancer diagnosis.”
Andrew Hardy, Chief Executive Officer of University Hospitals Coventry and Warwickshire NHS Trust, said: “This announcement is incredible news for patients and is testament to the hard work and dedication of our pathology team and their partners.
“Working through the new UHCW Institute of Precision Diagnostics and Translational medicine this allows UHCW to lead the way in translating new technologies to clinical practice.”